All News

New Jersey mandates new vaccinations for children

CVS Caremark Corp. fined for child labor violations

Merck recalls PedvaxHIB and COMVAX vaccines

Medicare fraud strike force lands five Miami firm execs in prison

NACDS applauds House passage of Pro-Soldier, Pro-Savings Bill

The CDC is developing a standards-based solution for sharing healthcare-associated infection data

PCI guideline update recommends long-term anticoagulation for DES

CHPA responds to NIDA's cough medicine abuse monitoring survey

Convenience Care Clinics to offer franchises nationwide

After suspending the Georgia Multistate Pharmacy Jurisprudence Examination in August, the National Association of Boards of Pharmacy announced that students can once again take the exam

FDA advisory panel rejects Merck's bid for OTC Mevacor

Azacitidine study shows five-day dosing schedule is efficacious

Glitazone study shows CV risk may be higher for elderly

Asians should receive genetic test prior to initiating carbamazepine

Drug Topics poll: R.Ph.s favor BTC class of drugs

Consumers Union opposes OTC Mevacor

FDA says long-term PPI use does not pose cardiovascular risk

NABP awards US Script's RxDirect VIPPS Accreditation

The Pharmacy Technician Certification Board is considering offering a new certification program in IV admixture as well as continuous testing

Gentium expands access to defibrotide under compassionate use basis

The Drug Enforcement Administration has suspended the license at a second Cardinal Health distribution facility located in Lakeland, Fla.

Longs Drugs to open walk-in medical clinic in Hawaii

CRN responds to Informed-Choice report calling for transparency in testing dietary supplements

Pharmacy directors see pipeline chock full of specialty drugs and compounds.

A trio of late-breaking clinical trials could change standard drug treatment for patients undergoing percutaneous coronary intervention, or PCI.

Company develops software to place barcodes on hospital's IV smart pumps, allowing it to track the pumps throughout the facility.

The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine (Xeloda) for patients with metastic or locally advanced breast cancer.

While there still is a great deal of variation in the MTM programs for 2007, pharmacist involvement has increased relative to the degree of pharmacist involvement in 2006.